Zimmer Biomet Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on August 17, 2023, reports significant senior leadership and Board of Director changes effective August 22, 2023. The filing details the departure of the long-serving CEO and the appointment of a new CEO, CFO, and Board Chairman.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
Material Changes Versus Prior Period
- CEO Departure: Bryan C. Hanson stepped down as Chairman, President, CEO, and Board member effective August 22, 2023. He will remain as an employee in an advisory capacity through August 31, 2023, at the same compensation level. No severance is triggered by his voluntary resignation.
- New CEO: Ivan Tornos, previously Chief Operating Officer, was appointed President and CEO and elected to the Board. He will not receive compensation for Board service.
- New Board Chairman: Christopher B. Begley, previously Lead Independent Director, was appointed Chairman of the Board.
- New CFO Role: Suketu Upadhyay was appointed to the newly created role of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain, expanding his previous duties to include global operations and supply chain oversight.
Guidance, Outlook, and Compensation Details
The filing outlines specific compensation packages for the new leadership team:
- Ivan Tornos (CEO):
- Base Salary: $1,200,000 annually.
- Target Bonus: Increased to 150% of base salary (prorated for 2023).
- One-time Equity (Sept 1, 2023): RSUs valued at ~$1.75 million and PRSUs valued at ~$1.75 million.
- Future Equity: Estimated 2024 annual grant value of ~$11.75 million.
- Severance: 2x (Base + Target Bonus) plus 24 months of COBRA for involuntary termination without cause. Change in Control provisions include 3x (Base + Target Bonus) and accelerated vesting.
- Perks: Personal aircraft use up to $190,000 incremental cost per year.
- Suketu Upadhyay (CFO):
- Base Salary: Increased to $850,000 annually.
- One-time Equity (Sept 1, 2023): PRSUs valued at ~$5.0 million, vesting over two performance periods.
- Future Equity: Estimated 2024 annual grant value of ~$4.0 million.
- Perks: Personal aircraft use up to $50,000 incremental cost per year.
- Sang Yi (Group President, Asia Pacific):
- One-time Equity (Sept 1, 2023): PRSUs valued at ~$250,000.
Investor Verification Checklist
- Verify the exact vesting schedules and performance metrics for the one-time PRSU grants to Tornos and Upadhyay.
- Review the full text of the Change in Control Severance Agreement (Exhibit 10.2) to understand specific "cause" and "good reason" definitions.
- Confirm the impact of the leadership transition on the company's strategic roadmap, as no operational guidance is provided in this filing.
- Check subsequent filings for the formal adoption of the 2024 equity grant values mentioned as estimates.